TavieRx, acquired by 360MedLink in 2013, is tackling the little regarded concern of treatment monitoring. The research was licensed to the company through Montréal University’s technology transfer office Univalor.
The technology has been clinically validated, is disease-specific and can be individually tailored to improve treatment adherence with real-time support. TavieRx includes the software VirtualNurse, which guides patients through the process of learning the skills to self-manage their chronic condition.
The technology won the Care Challenge 2012, organised by aid agency Care International, when it was adapted to eliminate childhood HIV with the aim of achieving that goal by 2015. TAVIE-HIV is a mobile application, which allows HIV-positive pregnant mothers to learn to manage their medication, improve adherence and stop maternal transmission.
360MedLink is a software company focused on the pharmaceutical and healthcare industry. It is dedicated to interactive multimedia solutions, digital communication, and also develops customised applications.
Jean Manassé Théagène, president of 360Medlink, said: “At 360Medlink we believe patient non-adherence is highly underestimated in terms of negative consequences on treatment efficacy, patient well-being and overall costs for public and private payers. The availability of TavieRx as a new tool clinically validated to show tangible results in various chronic disease indications is already receiving great interest from key healthcare stakeholders.”
